Trial Profile
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.